COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00066430
Recruitment Status : Completed
First Posted : August 7, 2003
Last Update Posted : September 17, 2014
National Cancer Institute (NCI)
Information provided by (Responsible Party):
AIDS Malignancy Consortium

Brief Summary:

RATIONALE: Infrared coagulation may be effective in preventing the development of anal cancer in patients who have anal neoplasia.

PURPOSE: Pilot study to evaluate the effectiveness of infrared coagulation in preventing anal cancer in HIV-positive patients who have high-grade anal neoplasia.

Condition or disease Intervention/treatment Phase
Anal Cancer Precancerous Condition Procedure: infrared photocoagulation therapy Device: Infrared Coagulator Phase 1

Detailed Description:


  • Determine the recurrence rate of high-grade squamous intraepithelial neoplasia in the anal canal of HIV-positive patients treated with infrared coagulation.
  • Determine the time to recurrence and time to progression in patients treated with this procedure.
  • Determine the toxicity of this procedure in these patients.
  • Correlate CD4/CD8 count and HIV viral load with outcome in patients treated with this procedure.
  • Correlate outcome with human papilloma virus subtype in patients treated with this procedure.

OUTLINE: This is an open-label, pilot, multicenter study.

Patients undergo treatment with an infrared coagulator in direct contact with the lesion for 1.5 seconds and necrotic tissue is then debrided. Treatment repeats to the level of the submucosal vessels under colposcopic guidance. A repeat biopsy is performed at 3 months to assess treatment success. Patients with incompletely treated lesions receive 1 more treatment. Up to 3 lesions are treated during each visit in the absence of disease progression or unacceptable toxicity.

Patients complete questionnaires regarding anal pain and discomfort at baseline, at 4 weeks, and at 3, 6, 9, and 12 months.

Patients are followed every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 18 patients will be accrued for this study within 6 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Infrared Coagulator For Treatment Of High Grade Squamous Intraepithelial Neoplasia (HSIL) in the Anal Canal In HIV Infected Individuals: A Pilot Study
Study Start Date : September 2003
Actual Primary Completion Date : September 2004
Actual Study Completion Date : April 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Infrared coagulator Procedure: infrared photocoagulation therapy
Device: Infrared Coagulator
IRC treatment of up to 3 HGAIN lesions at baseline (study initiation). A second IRC treatment may be administered for recurrent lesions at the 3 month visit.
Other Name: Redfield Infrared Coagulator (IRC) 2100

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • HIV positive
  • Presence of internal anal lesions with histologically confirmed high-grade squamous intraepithelial neoplasia with at least 1 positive margin

    • No more than 3 lesions, each no more than 10 mm in diameter
  • No evidence of microscopic invasion in any anal biopsy specimens
  • No history of anal cancer



  • Over 18

Performance status

  • Karnofsky 70-100%

Life expectancy

  • Not specified


  • Platelet count at least 50,000/mm^3
  • CD4 count at least 50 cells/mm^3


  • Not specified


  • Not specified


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No allergy to lidocaine
  • No anal insertions, including enemas or anal intercourse, for 24 hours before and at least 1 week after study treatment
  • No prior severe photosensitivity reaction
  • No active opportunistic infection
  • No concurrent neoplasia requiring cytotoxic therapy


Biologic therapy

  • Not specified


  • Not specified

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified


  • Must be on stable regimen of highly active antiretroviral therapy (HAART) for at least 12 weeks prior to study entry unless CD4 count > 200/mm^3 AND no plans to initiate HAART within the next 3 months
  • More than 14 days since prior acute treatment for an infection or other medical illness
  • No prior infrared coagulation for anal dysplasia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00066430

Layout table for location information
United States, California
UCSF Comprehensive Cancer Center
San Francisco, California, United States, 94143
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
AIDS Malignancy Consortium
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Elizabeth Stier, MD Memorial Sloan Kettering Cancer Center
Layout table for additonal information
Responsible Party: AIDS Malignancy Consortium Identifier: NCT00066430    
Other Study ID Numbers: AMC-032
CDR0000316109 ( Other Identifier: NCI )
First Posted: August 7, 2003    Key Record Dates
Last Update Posted: September 17, 2014
Last Verified: September 2014
Keywords provided by AIDS Malignancy Consortium:
anal cancer
high-grade squamous intraepithelial lesion
Additional relevant MeSH terms:
Layout table for MeSH terms
Anus Neoplasms
Precancerous Conditions
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Anus Diseases
Rectal Diseases